Document:

Exhibit 10.3

 

 

 

 

 

 

 

 

 

TAX
RECEIVABLE AGREEMENT

 

among

 

AROG
PHARMACEUTICALS HOLDINGS, INC.

 

AROG
PHARMACEUTICALS LLC

 

and

 

THE
PERSONS NAMED HEREIN

 

 

 

 

 

 

 

 

Dated
as of [•], 2018

 

 

 

 

 

 

 

 

 

 

     

     

    

 

Table
of CONTENTS

 

 

Page

 

	Article
    I  DEFINITIONS	4
	Section
    1.01  Definitions	4
	Article
    II  DETERMINATION OF REALIZED TAX BENEFIT	12
	Section
    2.01  Basis Adjustment	12
	Section
    2.02  Realized Tax Benefit and Realized Tax Detriment	12
	Section
    2.03  Procedures, Amendments	13
	Article
    III  TAX BENEFIT PAYMENTS	14
	Section
    3.01  Payments	14
	Section
    3.02  No Duplicative Payments	15
	Section
    3.03  Pro Rata Payments	15
	Article
    IV  TERMINATION	16
	Section
    4.01  Termination, Early Termination and Breach of Agreement	16
	Section
    4.02  Early Termination Notice	18
	Section
    4.03  Payment upon Early Termination	19
	Article
    V  SUBORDINATION AND LATE PAYMENTS	19
	Section
    5.01  Subordination	19
	Section
    5.02  Late Payments by the Corporate Taxpayer	19
	Article
    VI  NO DISPUTES; CONSISTENCY; COOPERATION	19
	Section
    6.01  Participation in the Corporate Taxpayer’s and OpCo’s Tax Matters	19
	Section
    6.02  Consistency	20
	Section
    6.03  Cooperation	20
	Article
    VII  MISCELLANEOUS	20
	Section
    7.01  Notices	20
	Section
    7.02  Binding Effect; Benefit; Assignment	21
	Section
    7.03  Resolution of Disputes	21
	Section
    7.04  Counterparts	23
	Section
    7.05  Entire Agreement	23
	Section
    7.06  Severability	23
	Section
    7.07  Amendment	23
	Section
    7.08  Governing Law	23
	Section
    7.09  Reconciliation	24

 

 

    i 

     

    

 

	Section
    7.10  Withholding	24
	Section
    7.11  Admission of the Corporate Taxpayer into a Consolidated Group; Transfers of Corporate Assets	25
	Section
    7.12  Confidentiality	25
	Section
    7.13  Change in Law	25
	Section
    7.14  Partnership Agreement	26

 

 

 

    ii 

     

    

TAX
RECEIVABLE AGREEMENT

 

This TAX RECEIVABLE
AGREEMENT (as amended from time to time, this “Agreement”), dated as of [•], 2018, is hereby entered into
by and among Arog Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Corporate Taxpayer”), Arog Pharmaceuticals
LLC, a Delaware limited liability company (“OpCo”), each of the Members (as defined below) from time to time
party thereto, and each of the successors and assigns thereto.

 

WHEREAS, the
OpCo is treated as a partnership for U.S. federal income tax purposes;

 

WHEREAS, the
Corporate Taxpayer is treated as a corporation for U.S. federal income tax purposes;

 

WHEREAS, [•]1
(the “Continuing LLC Owner”) holds common interest units in OpCo (the “Common Units”),
and following certain reorganization transactions, the Corporate Taxpayer will be the managing member of OpCo and will hold, directly
and/or indirectly, Common Units;

 

WHEREAS, on
and after the date hereof, pursuant to Section [•] of the LLC Agreement, the Continuing LLC Owner has the right, in its sole
discretion, from time to time to require OpCo to redeem (a “Redemption”) all or a portion of the Continuing
LLC Owner’s Common Units for cash or, at the Corporate Taxpayer’s option, shares of Class A common stock, $0.01 par
value per share, of the Corporate Taxpayer (the “Class A Common Stock”); provided that, pursuant to
Section [•] of the LLC Agreement and at the election of the Corporate Taxpayer, the Corporate Taxpayer may effect a direct
exchange (a “Direct Exchange,” and together with a Redemption, an “Exchange”) of such cash
or shares of Class A Common Stock for such Common Units;

 

WHEREAS, OpCo
and each of its direct and indirect subsidiaries, if any, treated as a partnership for U.S. federal income tax purposes will have
in effect an election under Section 754 of the Internal Revenue Code of 1986, as amended (the “Code”), for
each Taxable Year (as defined below) in which an Exchange occurs, which elections are intended generally to result in an adjustment
to the tax basis of the assets owned by OpCo (solely with respect to the Corporate Taxpayer) at the time of an Exchange (such
time, the “Exchange Date”) by reason of the Exchange and the receipt of payments under this Agreement;

 

WHEREAS, the
income, gain, loss, expense and other Tax (as defined below) items of the Corporate Taxpayer may be affected by (i) the Basis
Adjustment (as defined below) and (ii) Imputed Interest (as defined below); and

 

 

 

 

 

 

1
Note to Draft: To be New Arog S-Corp.

 

     

     

    

WHEREAS, the
parties to this Agreement desire to make certain arrangements with respect to the effect of the Basis Adjustment and Imputed Interest
on the actual liability for Taxes of the Corporate Taxpayer.

 

NOW, THEREFORE,
in consideration of the foregoing and the respective covenants and agreements set forth herein, and intending to be legally bound
hereby, the parties hereto agree as follows:

 

Article
I

DEFINITIONS

 

Section 1.01           
Definitions.

 

(a)                
The following terms shall have the following meanings for the purposes of this Agreement:

 

“Actual
Tax Liability” means, with respect to any Taxable Year, the actual liability for U.S. federal, state and local income
Taxes of (i) the Corporate Taxpayer and (ii) without duplication, OpCo, but only with respect to Taxes imposed on OpCo and allocable
to the Corporate Taxpayer (or to any other member of the consolidated group, if any, of which the Corporate Taxpayer is the parent)
for such Taxable Year.

 

“Affiliate”
means, with respect to any Person, any other Person that directly or indirectly, through one or more intermediaries, Controls,
is Controlled by, or is under common Control with, such Person.

 

“Agreed
Rate” means a per annum rate of LIBOR plus 100 basis points.

 

“Applicable
Member” means any Member to whom or which any portion of a Realized Tax Benefit may be Attributable under this Agreement.

 

A Net Tax Benefit
is “Attributable” to a Member to the extent that it is derived from any Basis Adjustment or Imputed Interest
that is attributable to an Exchange undertaken by or with respect to such Member, and portions of any Realized Tax Detriment shall
be Attributed to Members under similar principles. If a Person becomes a Member pursuant to ‎Section
7.02(b), each reference to such Member in the immediately preceding sentence shall include a reference to such Member’s
predecessors in interest, but only to the extent commensurate with the rights hereunder transferred, directly or indirectly, to
such Member by such predecessors, and, if any such predecessor in interest continues as a Member, the preceding sentence shall
be applied to such predecessor as though, to the extent commensurate with the rights hereunder transferred by such predecessor,
such predecessor had never been a Member.

 

“Basis
Adjustment” means the adjustment to the tax basis of a Reference Asset under Sections 732, 755 and 1012 of the Code
and the Treasury Regulations promulgated thereunder (in situations where, as a result of one or more Exchanges, OpCo

 

    4

     

    

becomes an
entity that is disregarded as separate from its owner for U.S. federal income tax purposes) or under Sections 743(b) and 755 of
the Code and the Treasury Regulations promulgated thereunder (in situations where, following an Exchange, OpCo remains in existence
as an entity for U.S. federal income tax purposes) and, in each case, comparable sections of state and local tax laws, as a result
of (i) an Exchange and (ii) the payments made pursuant to the Tax Receivable Agreements. For the avoidance of doubt, the amount
of any Basis Adjustment resulting from an Exchange of one or more Common Units shall be determined without regard to any Pre-
Exchange Transfer of such Common Units and as if any such Pre-Exchange Transfer had not occurred.

 

A “Beneficial
Owner” of a security is a Person who directly or indirectly, through any contract, arrangement, understanding, relationship
or otherwise, has or shares: (i) voting power, which includes the power to vote, or to direct the voting of, such security and/or
(ii) investment power, which includes the power to dispose of, or to direct the disposition of, such security.

 

“Blended
Rate” means, with respect to any Taxable Year, the sum of the effective rates of tax imposed on the aggregate net income
of the Corporate Taxpayer in each state or local jurisdiction in which the Corporate Taxpayer files Tax Returns for such Taxable
Year, with the maximum effective rate in any state or local jurisdiction being equal to the product of: (i) the apportionment
factor on the income or franchise Tax Return filed by the Corporate Taxpayer in such jurisdiction for such Taxable Year, and (ii)
the maximum applicable corporate tax rate in effect in such jurisdiction in such Taxable Year. As an illustration of the calculation
of Blended Rate for a Taxable Year, if the Corporate Taxpayer solely files Tax Returns in State 1 and State 2 in a Taxable Year,
the maximum applicable corporate tax rates in effect in such states in such Taxable Year are 6% and 5%, respectively and the apportionment
factors for such states in such Taxable Year are 60% and 40%, respectively, then the Blended Rate for such Taxable Year is equal
to 5.6% (i.e., 6% times 60% plus 5% times 40%).

 

“Board”
means the board of directors of the Corporate Taxpayer.

 

“Business
Day” shall have the meaning ascribed to such term in the LLC Agreement.

 

“Change
of Control” means the occurrence of any of the following events:

 

(i)       any
Person or any group of Persons acting together which would constitute a “group” for purposes of Section 13(d) of the
Securities and Exchange Act of 1934, or any successor provisions thereto, excluding (x) a corporation or other entity owned, directly
or indirectly, by the stockholders of the Corporate Taxpayer in substantially the same proportions as their ownership of stock
in the Corporate Taxpayer and (y) any Member or any of its Affiliates who is or becomes the Beneficial Owner, directly or indirectly,
of securities of the Corporate Taxpayer representing more than 50% of the combined voting power of the Corporate Taxpayer’s
then outstanding voting securities;

 

    5

     

    

(ii)       the
following individuals cease to constitute a majority of the number of directors of the Corporate Taxpayer then serving: individuals
who, on the IPO Date, constitute the Board and any new director whose appointment or election by the Board or nomination for election
by the Corporate Taxpayer’s shareholders was approved or recommended by a vote of at least a majority of the directors then
still in office who either were directors on the IPO Date or whose appointment, election or nomination for election was previously
so approved or recommended by the directors referred to in this clause (ii);

 

(iii)       there
is consummated a merger or consolidation of the Corporate Taxpayer with any other corporation or other entity, and, immediately
after the consummation of such merger or consolidation, either (x) the Board immediately prior to the merger or consolidation
does not constitute at least a majority of the board of directors of the company surviving the merger or, if the surviving company
is a Subsidiary, the ultimate parent thereof, or (y) the voting securities of the Corporate Taxpayer immediately prior to such
merger or consolidation do not continue to represent or are not converted into more than 50% of the combined voting power of the
then outstanding voting securities of the Person resulting from such merger or consolidation or, if the surviving company is a
Subsidiary, the ultimate parent thereof; or

 

(iv)       the
shareholders of the Corporate Taxpayer approve a plan of complete liquidation or dissolution of the Corporate Taxpayer or there
is consummated an agreement or series of related agreements for the sale or other disposition, directly or indirectly, by the
Corporate Taxpayer of all or substantially all of the Corporate Taxpayer’s assets, other than such sale or other disposition
by the Corporate Taxpayer of all or substantially all of the Corporate Taxpayer’s assets to an entity, at least 50% of the
combined voting power of the voting securities of which are owned by shareholders of the Corporate Taxpayer in substantially the
same proportions as their ownership of the Corporate Taxpayer immediately prior to such sale.

 

Notwithstanding the foregoing,
except with respect to clause (ii) and clause (iii) above, a “Change of Control” shall not be deemed to have occurred
by virtue of the consummation of any transaction or series of integrated transactions immediately following which the record holders
of the shares of the Corporate Taxpayer immediately prior to such transaction or series of transactions continue to have substantially
the same proportionate ownership in, and own substantially all of the shares of, an entity which owns all or substantially all
of the assets of the Corporate Taxpayer immediately following such transaction or series of transactions.

 

“Control”
means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person,
whether through ownership of voting securities, by contract or otherwise.

 

“Corporate
Taxpayer Return” means the U.S. federal and/or state and/or local Tax Return, as applicable, of the Corporate Taxpayer
filed with respect to Taxes of any Taxable Year.

 

    6

     

    

“Cumulative
Net Realized Tax Benefit” for a Taxable Year means the cumulative amount of Realized Tax Benefits for all Taxable Years
of the Corporate Taxpayer, up to and including such Taxable Year, net of the cumulative amount of Realized Tax Detriments for
the same period. The Realized Tax Benefit and Realized Tax Detriment for each Taxable Year shall be determined based on the most
recent Tax Benefit Schedule or Amended Schedule, if any, in existence at the time of such determination.

 

“Default
Rate” means a per annum rate of LIBOR plus 500 basis points.

 

“Determination”
shall have the meaning ascribed to such term in Section 1313(a) of the Code or similar provision of state and local tax law, as
applicable, or any other event (including the execution of IRS Form 870-AD) that finally and conclusively establishes the amount
of any liability for Tax and shall also include the acquiescence of the Corporate Taxpayer to the amount of any assessed liability
for Tax.

 

“Direct
Exchange” is defined in the recitals to this Agreement.

 

“Early
Termination Date” means the date of an Early Termination Notice for purposes of determining the Early Termination Payment.

 

“Early
Termination Rate” means a per annum rate of the lesser of (i) 6.5% per annum, compounded annually, and (ii) LIBOR plus
100 basis points.

 

“Exchange”
is defined in the recitals to this Agreement.

 

“Governmental
Authority” has the meaning set forth in the LLC Agreement.

 

“Hypothetical
Federal Tax Liability” means, with respect to any Taxable Year, the liability for U.S. federal income Taxes of (i) the
Corporate Taxpayer and (ii) without duplication, OpCo, but only with respect to U.S. federal income Taxes imposed on OpCo and
allocable to the Corporate Taxpayer (or to the other members of the consolidated group of which the Corporate Taxpayer is the
parent), in each case using the same methods, elections, conventions and similar practices used on the relevant Corporate Taxpayer
Return, but (w) using the Non-Stepped Up Tax Basis as reflected on the applicable Exchange Basis Schedule, including amendments
thereto for the Taxable Year, (x) excluding any deduction attributable to Imputed Interest for the Taxable Year, (y) deducting
the Hypothetical Other Tax Liability (rather than any amount for state, local or foreign tax liabilities) for such Taxable Year
and (z) without taking into account the carryover or carryback of any Tax item (or portions thereof) that is attributable to or
(without duplication) available for use because of the prior use of any of the Basis Adjustments or Imputed Interest.

 

“Hypothetical
Other Tax Liability” means, with respect to any Taxable Year, U.S. federal taxable income determined in connection with
calculating the Hypothetical Federal Tax Liability for such Taxable Year (determined without regard to clause (y) thereof) multiplied
by the Blended Rate for such Taxable Year.

 

    7

     

    

“Hypothetical
Tax Liability” means, with respect to any Taxable Year, the Hypothetical Federal Tax Liability for such Taxable Year,
plus the Hypothetical Other Tax Liability for such Taxable Year.

 

“Imputed
Interest” shall mean any interest imputed under Section 1272, 1274 or 483 or other provision of the Code and any similar
provision of state and local tax law with respect to the Corporate Taxpayer’s payment obligations under this Agreement.

 

“IPO”
means the initial public offering of Class A Common Stock of the Corporate Taxpayer.

 

“IPO
Date” means the closing date of the IPO.

 

“IRS”
means the U.S. Internal Revenue Service.

 

“LIBOR”
means during any period, the rate which appears on the Bloomberg Page BBAM1 (or on such other substitute Bloomberg page that displays
rates at which U.S. dollar deposits are offered by leading banks in the London interbank deposit market), or the rate which is
quoted by another source selected by the Corporation as an authorized information vendor for the purpose of displaying rates at
which U.S. dollar deposits are offered by leading banks in the London interbank deposit market (an “Alternate Source”),
at approximately 11:00 a.m., London time, two (2) Business Days prior to the first day of such period as the London interbank
offered rate for U.S. dollars having a borrowing date and a maturity comparable to such period (or if there shall at any time,
for any reason, no longer exist a Bloomberg Page BBAM1 (or any substitute page) or any LIBOR Alternate Source, a comparable replacement
rate determined by the Corporation at such time, which determination shall be conclusive absent manifest error; provided, that
at no time shall LIBOR be less than 0%.

 

“LLC
Agreement” means the Amended and Restated Limited Liability Company Agreement of OpCo, dated as of the date hereof.

 

“Market
Value” shall mean the closing price of the Class A Common Stock on the applicable Exchange Date on the national securities
exchange or interdealer quotation system on which such Class A Common Stock is then traded or listed, as reported by the Wall
Street Journal; provided, that if the closing price is not reported by the Wall Street Journal for the applicable
Exchange Date, then the Market Value shall mean the closing price of the Class A Common Stock on the Business Day immediately
preceding such Exchange Date on the national securities exchange or interdealer quotation system on which such Class A Common
Stock is then traded or listed, as reported by the Wall Street Journal; provided, further, that if the Class
A Common Stock is not then listed on a national securities exchange or interdealer quotation system, the Market Value shall mean
the cash consideration paid for Class A Common Stock, or the fair market value of the other property delivered for Class A Common
Stock, as determined by the Board in good faith.

 

    8

     

    

“Member”
means the Continuing LLC Owner, as well as any transferee agreeing to become a Member pursuant to ‎Section
7.02(b) of this Agreement.

 

“Non-Stepped
Up Tax Basis” means, with respect to any Reference Asset at any time, the Tax basis that such asset would have had at
such time if no Basis Adjustments had been made.

 

“Payment
Date” means any date on which a payment is required to be made pursuant to this Agreement.

 

“Person”
means any individual, corporation, firm, partnership, joint venture, limited liability company, estate, trust, business association,
organization, governmental entity or other entity.

 

“Pre-Exchange
Transfer” means any transfer or distribution in respect of one or more Common Units (i) that occurs prior to an Exchange
of such Common Units, and (ii) to which Section 743(b) or 734(b) of the Code applies.

 

“Realized
Tax Benefit” means, for a Taxable Year, the excess, if any, of the Hypothetical Tax Liability over the Actual Tax Liability.
If all or a portion of the Actual Tax Liability for such Taxable Year arises as a result of an audit or similar proceeding by
a Taxing Authority of any Taxable Year, such liability shall not be included in determining the Realized Tax Benefit unless and
until there has been a Determination with respect to such Actual Tax Liability.

 

“Realized
Tax Detriment” means, for a Taxable Year, the excess, if any, of the Actual Tax Liability over the Hypothetical Tax
Liability. If all or a portion of the Actual Tax Liability for such Taxable Year arises as a result of an audit or similar proceeding
by a Taxing Authority of any Taxable Year, such liability shall not be included in determining the Realized Tax Detriment unless
and until there has been a Determination with respect to such Actual Tax Liability.

 

“Redemption”
has the meaning in the recitals to this Agreement.

 

“Reference
Asset” means an asset that is held by OpCo, or by any of its direct or indirect subsidiaries, if any, treated as a partnership
or disregarded entity for purposes of the applicable Tax, at the time of an Exchange. A Reference Asset also includes any asset
that is “substituted basis property” under Section 7701(a)(42) of the Code with respect to a Reference Asset.

 

“Schedule”
means any of the following: (i) an Exchange Basis Schedule, (ii) a Tax Benefit Schedule, or (iii) the Early Termination Schedule.

 

“Subsidiaries”
shall have the meaning ascribed to such term in the LLC Agreement.

 

“Subsidiary
Stock” means any stock or other equity interest in any Subsidiary of the Corporate Taxpayer that is (i) treated as a
corporation for U.S. federal

 

    9

     

    

income tax
purposes and (ii) a member of an affiliated or consolidated group of corporations that files a consolidated income tax return
pursuant to Sections 1501 et seq. of the Code with respect to which the Corporate Taxpayer is a member.

 

“Tax
Return” means any return, declaration, report or similar statement required to be filed with respect to Taxes (including
any attached schedules), including any information return, claim for refund, amended return and declaration of estimated Tax.

 

“Taxable
Year” means a taxable year of the Corporate Taxpayer as defined in Section 441(b) of the Code or comparable section
of state or local tax law, as applicable (and, therefore, for the avoidance of doubt, may include a period of less than 12 months
for which a Tax Return is made), ending on or after the IPO Date.

 

“Taxes”
means any and all taxes, assessments or similar charges that are based on or measured with respect to net income or profits, and
any interest related to such Tax.

 

“Taxing
Authority” shall mean any domestic, federal, national, state, county or municipal or other local government, any subdivision,
agency, commission or authority thereof, or any quasi-governmental body exercising any taxing authority or any other authority
exercising Tax regulatory authority.

 

“Treasury
Regulations” means the final, temporary and proposed regulations under the Code promulgated from time to time (including
corresponding provisions and succeeding provisions) as in effect for the relevant taxable period.

 

“Valuation
Assumptions” shall mean, as of an Early Termination Date, the assumptions that (1) in each Taxable Year ending on or
after such Early Termination Date, the Corporate Taxpayer will have taxable income sufficient to fully utilize the deductions
arising from the Basis Adjustments and Imputed Interest during such Taxable Year or future Taxable Years (including, for the avoidance
of doubt, Basis Adjustments and Imputed Interest that would result from future Tax Benefit Payments that would be paid in accordance
with the Valuation Assumptions) in which such deductions would become available, (2) the U.S. federal income tax rates and state
and local income tax rates that will be in effect for each such Taxable Year will be those specified for each such Taxable Year
by the Code and other law as in effect on the Early Termination Date, (3) any loss or credit carryovers generated by deductions
arising from Basis Adjustments or Imputed Interest that are available as of such Early Termination Date will be utilized by the
Corporate Taxpayer on a pro rata basis in each Taxable Year over the five Taxable Years beginning with the Taxable Year that includes
the Early Termination Date, (4) any non-amortizable assets (other than Subsidiary Stock) will be disposed of on the fifteenth
anniversary of the applicable Basis Adjustment in a fully taxable transaction for U.S. federal income tax purposes for an amount
sufficient to fully utilize the Basis Adjustments with respect to such non-amortizable assets; provided, that in the event of
a Change of Control, such non-amortizable assets shall be deemed disposed of at the time of sale of the relevant asset (if earlier
than such fifteenth anniversary), (5) any Subsidiary

 

    10

     

    

Stock will
be deemed never to be disposed of and (6) if, at the Early Termination Date, there are Common Units (other than those held by
the Corporate Taxpayer) that have not been Exchanged, then each such Common Unit shall be deemed to be Exchanged for the product
of (i) the Market Value of the Class A Common Stock on the Early Termination Date and (ii) the number of shares of Class A Common
Stock that would be transferred in respect of such Common Unit if the Exchange occurred on the Early Termination Date. For purposes
of clause (4) above, a transfer of a partnership interest shall be treated as a transfer of the transferring partner’s share
of each of the assets and liabilities of that partnership.

 

(b)                
Each of the following terms is defined in the Section set forth opposite such term:

 

	Term	Section
	Agreement	Preamble
	Amended Schedule	‎2.03(b)
	Class A Common Stock	Recitals
	Code	Recitals
	Common Units	Recitals
	Corporate Taxpayer 	Preamble
	Dispute 	‎7.03(a)
	Early Termination Effective Date	‎4.02
	Early Termination Notice	‎4.02
	Early Termination Payment	‎4.03(b)
	Early Termination Schedule	‎4.02
	e-mail	‎7.01
	Exchange Basis Schedule	‎2.01
	Exchange Date	Recitals
	Expert	‎7.09
	Interest Amount	‎3.01(b)
	Material Objection Notice	‎4.02
	Net Tax Benefit	‎3.01(b)
	Objection Notice	‎2.03(a)
	OpCo	Recitals
	Reconciliation Dispute	‎7.09
	Reconciliation Procedures	‎2.03(a)
	Senior Obligations	‎5.01
	Tax Benefit Payment	‎3.01(b)
	Tax Benefit Schedule	‎2.02(a)
	Tax Proceeding	6.01(a)

 

(c)                
Other Definitional and Interpretative Provisions. The words “hereof”, “herein” and “hereunder”
and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of
this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or
interpretation hereof. References to Articles and Sections are to Articles and Sections of this Agreement unless otherwise specified.
Any singular term in

 

    11

     

    

this
Agreement shall be deemed to include the plural, and any plural term the singular. Whenever the words “include”, “includes”
or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation”,
whether or not they are in fact followed by those words or words of like import. “Writing”, “written”
and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible
form. References to any statute shall be deemed to refer to such statute as amended from time to time and to any rules or regulations
promulgated thereunder. References to any agreement or contract are to that agreement or contract as amended, modified or supplemented
from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted
assigns of that Person. References from or through any date mean, unless otherwise specified, from and including or through and
including, respectively.

 

Article
II

DETERMINATION OF REALIZED TAX BENEFIT

 

Section 2.01           
Basis Adjustment. Within 120 calendar days after the filing of the federal income tax return of the Corporate Taxpayer
for each Taxable Year in which any Exchange has been effected by any Member, the Corporate Taxpayer shall deliver to each such
Member a schedule (the “Exchange Basis Schedule”) that shows, in reasonable detail necessary to perform the
calculations required by this Agreement, including with respect to each Exchanging party, (i) the Non-Stepped Up Tax Basis of
the Reference Assets as of each applicable Exchange Date, (ii) the Basis Adjustments with respect to the Reference Assets as a
result of each Exchange effected in such Taxable Year, calculated (x) in the aggregate, and (y) solely with respect to Exchanges
by such Member, (iii) the period (or periods) over which the Reference Assets are amortizable and/or depreciable and (iv) the
period (or periods) over which each Basis Adjustment is amortizable and/or depreciable. For the avoidance of doubt, payments made
under this Agreement shall not be treated as resulting in a Basis Adjustment to the extent such payments are treated as Imputed
Interest.

 

Section 2.02           
Realized Tax Benefit and Realized Tax Detriment.

 

(a)                
Tax Benefit Schedule. Within 120 calendar days after the filing of the U.S. federal income tax return of the Corporate
Taxpayer for any Taxable Year in which any Exchange has been effected by a Member or which is subsequent to any Taxable Year in
which any Exchange has been effected by a Member, the Corporate Taxpayer shall provide to such Member a schedule showing, in reasonable
detail, the calculation of the Realized Tax Benefit or Realized Tax Detriment and the portion Attributable to such Member for
such Taxable Year (a “Tax Benefit Schedule”). The Tax Benefit Schedule will become final as provided in ‎Section
2.03(a) and may be amended as provided in ‎Section 2.03(b) (subject to the procedures set forth in ‎Section
2.03(b)).

 

(b)                
Applicable Principles. The Realized Tax Benefit or Realized Tax Detriment for each Taxable Year is intended to measure
the decrease or increase in the Actual Tax Liability of the Corporate Taxpayer for such Taxable Year attributable to

 

    12

     

    

the
Basis Adjustments and Imputed Interest, determined using a “with and without” methodology. For the avoidance of doubt,
the Actual Tax Liability will take into account the deduction of the portion of the Tax Benefit Payment that must be accounted
for as interest under the Code based upon the characterization of Tax Benefit Payments as additional consideration payable by
the Corporate Taxpayer for the Common Units acquired in an Exchange. Carryovers or carrybacks of any Tax item attributable to
the Basis Adjustment or Imputed Interest shall be considered to be subject to the rules of the Code and the Treasury Regulations
or the appropriate provisions of U.S. state and local income and franchise tax law, as applicable, governing the use, limitation
and expiration of carryovers or carrybacks of the relevant type. If a carryover or carryback of any Tax item includes a portion
that is attributable to the Basis Adjustment or Imputed Interest and another portion that is not, such portions shall be considered
to be used in accordance with the “with and without” methodology. The parties agree that (i) all Tax Benefit Payments
attributable to the Basis Adjustments (other than amounts accounted for as interest under the Code) will (A) be treated as subsequent
upward purchase price adjustments that give rise to further Basis Adjustments to Reference Assets for the Corporate Taxpayer and
(B) have the effect of creating additional Basis Adjustments to Reference Assets for the Corporate Taxpayer in the year of payment,
and (ii) as a result, such additional Basis Adjustments will be incorporated into the current year calculation and into future
year calculations, as appropriate.

 

Section 2.03           
Procedures, Amendments.

 

(a)                
Procedure. Every time the Corporate Taxpayer delivers to a Member an applicable Schedule under this Agreement, including
any Amended Schedule delivered pursuant to ‎Section
2.03(b) and any Early Termination Schedule or amended Early Termination Schedule, the Corporate Taxpayer shall also (x) deliver
to such Member schedules and work papers, as determined by the Corporate Taxpayer or requested by such Member, providing reasonable
detail regarding the preparation of the Schedule and (y) allow such Member reasonable access to the appropriate representatives
at the Corporate Taxpayer, as determined by the Corporate Taxpayer, in connection with a review of such Schedule. Without limiting
the application of the preceding sentence, each time the Corporate Taxpayer delivers to a Member a Tax Benefit Schedule, in addition
to the Tax Benefit Schedule duly completed, the Corporate Taxpayer shall deliver to such Member the Corporate Taxpayer Return,
the reasonably detailed calculation by the Corporate Taxpayer of the Hypothetical Tax Liability, the reasonably detailed calculation
by the Corporate Taxpayer of the Actual Tax Liability, as well as any other work papers as determined by the Corporate Taxpayer
or requested by such Member, provided that the Corporate Taxpayer shall be entitled to redact any information that it reasonably
believes is unnecessary for purposes of determining the items in the applicable Schedule or amendment thereto. An applicable Schedule
or amendment thereto shall become final and binding on the applicable Member and the Corporate Taxpayer thirty (30) calendar days
from the first date on which the Member has received the applicable Schedule or amendment thereto unless such Member (i) within
thirty (30) calendar days after receiving an applicable Schedule or amendment thereto, provides the Corporate Taxpayer with notice
of a material objection to such Schedule (“Objection Notice”) made in good faith or (ii) provides a written
waiver of such right of any

 

    13

     

    

Objection
Notice within the period described in clause ‎(i) above, in which case such Schedule or amendment thereto becomes binding
on the date the waiver is received by the Corporate Taxpayer. If the applicable Member and the Corporate Taxpayer for any reason,
are unable to successfully resolve the issues raised in the Objection Notice within thirty (30) calendar days after receipt by
the Corporate Taxpayer of an Objection Notice, the Corporate Taxpayer and the applicable Member shall employ the reconciliation
procedures as described in ‎Section 7.09 (the “Reconciliation Procedures”).

 

(b)                
Amended Schedule. The applicable Schedule for any Taxable Year may be amended from time to time by the Corporate
Taxpayer (i) in connection with a Determination affecting such Schedule, (ii) to correct inaccuracies in the Schedule identified
as a result of the receipt of additional factual information relating to a Taxable Year after the date the Schedule was provided
to the applicable Member, (iii) to comply with the Expert’s determination under the Reconciliation Procedures, (iv) to reflect
a change in the Realized Tax Benefit or Realized Tax Detriment for such Taxable Year attributable to a carryback or carryforward
of a loss or other tax item to such Taxable Year, (v) to reflect a change in the Realized Tax Benefit or Realized Tax Detriment
for such Taxable Year attributable to an amended Tax Return filed for such Taxable Year, or ((vi) to adjust the Exchange Basis
Schedule to take into account payments made pursuant to this Agreement (any such Schedule, an “Amended Schedule”).
The Corporate Taxpayer shall provide an Amended Schedule to each relevant Member within thirty (30) calendar days of the occurrence
of an event referenced in clauses ‎(i) through ‎(vi) of the preceding sentence.

 

Article
III

TAX BENEFIT PAYMENTS

 

Section 3.01           
Payments.

 

(a)                
Within five (5) Business Days after all of the Tax Benefit Schedules (as defined in each of the Tax Receivable Agreements)
with respect to a Taxable Year delivered to any Member become final in accordance with ‎Section
2.03(a), the Corporate Taxpayer shall pay to each Member for such Taxable Year the Tax Benefit Payment in the amount determined
pursuant to ‎Section 3.01(b). Each such Tax Benefit Payment to a Member shall be made by wire transfer of immediately
available funds to the bank account previously designated by such Member to the Corporate Taxpayer or as otherwise agreed by the
Corporate Taxpayer and such Member. For the avoidance of doubt, no Tax Benefit Payment shall be made in respect of estimated tax
payments, including federal estimated income tax payments.

 

Notwithstanding any provision
of this Agreement to the contrary, any Member may elect with respect to any Exchange to limit the aggregate Tax Benefit Payments
made to such Member in respect of any such Exchange to a specified percentage of the amount equal to the sum of (A) the cash,
excluding any Tax Benefit Payments, and (B) the Market Value of the Class A Shares received by such Member on such Exchange (or
such other limitation selected by the Member and consented to by the Corporate Taxpayer, which

 

    14

     

    

consent shall not be unreasonably
withheld). The Member shall exercise its rights under the preceding sentence by notifying the Corporate Taxpayer in writing of
its desire to impose such a limit and the specified percentage (or such other limitation selected by the Member) and such other
details as may be necessary (including whether such limit includes the Imputed Interest in respect of any such Exchange) in such
manner and at such time (but in no event later than the date of any such Exchange) as reasonably directed by the Corporate Taxpayer;
provided, however, that, in the absence of such direction, the Member shall give such written notice in the same
manner as is required by ‎Section 7.01 of this Agreement contemporaneously with Member’s notice to the Corporate Taxpayer
of the applicable Exchange.

 

(b)                
A “Tax Benefit Payment” means, with respect to a Member, an amount, not less than zero, equal to the
sum of the amount of the Net Tax Benefit Attributable to such Member and the related Interest Amount. For the avoidance of doubt,
for Tax purposes, the Interest Amount shall not be treated as interest but instead shall be treated as additional consideration
for the acquisition of Common Units in Exchanges, unless otherwise required by law. Subject to ‎Section 3.03(a), the
“Net Tax Benefit” for a Taxable Year shall be an amount equal to the excess, if any, of 85% of the Cumulative
Net Realized Tax Benefit as of the end of such Taxable Year over the total amount of Tax Benefit Payments previously made under
this ‎Section 3.01 (excluding payments attributable to Interest Amounts); provided, for the avoidance of doubt,
that such Member shall not be required to return any portion of any previously made Tax Benefit Payment. The “Interest
Amount” shall equal the interest on the amount of the Net Tax Benefit Attributable to such Member calculated at the
Agreed Rate from the due date (without extensions) for filing the Corporate Taxpayer Return with respect to Taxes for such Taxable
Year until the Payment Date of the applicable Tax Benefit Payment. Notwithstanding anything to the contrary in this Agreement,
after any lump-sum payment under ‎Article IV of this Agreement in respect of present or future Tax attributes subject
to this Agreement, the Tax Benefit Payment, Net Tax Benefit and components thereof shall be calculated without taking into account
any such attributes or any such lump-sum payment.

 

Section 3.02           
No Duplicative Payments. It is intended that the provisions of this Agreement will not result in duplicative payment
of any amount (including interest) required under this Agreement. The provisions of this Agreement shall be construed in the appropriate
manner to ensure such intentions are realized.

 

Section 3.03           
Pro Rata Payments.

 

(a)                
Notwithstanding anything in ‎Section 3.01 to
the contrary, to the extent that the aggregate tax benefit of the Corporate Taxpayer’s reduction in Tax liability as a result
of the Basis Adjustments and Imputed Interest under this Agreement is limited in a particular Taxable Year because the Corporate
Taxpayer does not have sufficient taxable income to fully utilize available deductions and other attributes, the limitation on
the tax benefit for the Corporate Taxpayer shall be allocated among the Members in proportion to the respective amounts of Tax
Benefit Payments that would have been determined under this Agreement if the Corporate Taxpayer had sufficient

 

    15

     

    

taxable
income so that there were no such limitation; provided, that for purposes of allocating among the Members the aggregate
Tax Benefit Payments under this Agreement with respect to any Taxable Year, the operation of this ‎Section 3.03(a)
with respect to any prior Taxable Year shall be taken into account, it being the intention of the Corporate Taxpayer and the Members
for each Member to receive, in the aggregate, Tax Benefit Payments in proportion to the aggregate Net Tax Benefits Attributable
to such Member had this ‎Section 3.03(a) never operated.

 

(b)                
After taking into account ‎Section 3.03(a),
if for any reason the Corporate Taxpayer does not fully satisfy its payment obligations to make all Tax Benefit Payments due under
this Agreement in respect of a particular Taxable Year, then the Corporate Taxpayer and the Members agree that (i) the Corporate
Taxpayer shall pay the same proportion of each Tax Benefit Payment due under this Agreement in respect of such Taxable Year, without
favoring one obligation over the other, and (ii) no Tax Benefit Payment shall be made in respect of any Taxable Year until all
Tax Benefit Payments in respect of prior Taxable Years have been made in full.

 

(c)                
To the extent the Corporate Taxpayer makes a payment to a Member in respect of a particular Taxable Year under ‎Section
3.01(a) of this Agreement (taking into account ‎Section
3.03(a) and ‎(b), but excluding payments attributable
to Interest Amounts) in excess of the amount of such payment that should have been made to such Member in respect of such Taxable
Year, then (i) such Member shall not receive further payments under ‎Section 3.01(a) until such Member has foregone
an amount of payments equal to such excess and (ii) the Corporate Taxpayer shall pay the amount of such Member’s foregone
payments to the other Members in a manner such that each of the other Members, to the maximum extent possible, shall have received
aggregate payments under ‎Section 3.01(a) of this Agreement (excluding payments attributable to Interest Amounts) in
the amount it would have received if there had been no excess payment to such Member.

 

Article
IV

TERMINATION

 

Section 4.01           
Termination, Early Termination and Breach of Agreement.

 

(a)                
Unless terminated earlier pursuant to ‎Section
4.01(b), ‎Section 4.01(c) or ‎Section
4.01(d), this Agreement will terminate when there is no further potential for a Tax Benefit Payment pursuant to this Agreement.
Tax Benefit Payments under this Agreement are not conditioned on any Member retaining an interest in the Corporate Taxpayer or
OpCo (or any successor thereto).

 

(b)                
The Corporate Taxpayer may terminate this Agreement with respect to all amounts payable to the Members and with respect
to all of the Common Units held (or previously held and Exchanged) by all Members at any time by paying to each Member the Early
Termination Payment in respect of such Member; provided,

 

    16

     

    

however,
that this Agreement shall only terminate pursuant to this ‎Section 4.01(b) upon the receipt of the Early Termination
Payment by all Members; and provided, further, that the Corporate Taxpayer may withdraw any notice to exercise its
termination rights under this ‎Section 4.01(b) prior to the time at which any Early Termination Payment has been paid.
Upon payment of the Early Termination Payment by the Corporate Taxpayer in accordance with this ‎Section 4.01(b), neither
the Members nor the Corporate Taxpayer shall have any further payment obligations under this Agreement, other than for any (i)
Tax Benefit Payment agreed to by the Corporate Taxpayer and a Member as due and payable but unpaid as of the Early Termination
Notice and (ii) Tax Benefit Payment due for the Taxable Year ending with or including the date of the Early Termination Notice
(except to the extent that the amount described in clause (ii) is included in the Early Termination Payment). If an Exchange occurs
after the Corporate Taxpayer makes the Early Termination Payment pursuant to this ‎Section 4.01(b), the Corporate Taxpayer
shall have no obligations under this Agreement with respect to such Exchange.

 

(c)                
In the event of a Change of Control, all payment obligations hereunder shall be accelerated and such obligations shall
be calculated as if an Early Termination Notice had been delivered on the effective date of the Change of Control and shall include,
but not be limited to, (x) the Early Termination Payment calculated as if an Early Termination Notice had been delivered on the
effective date of the Change of Control, (y) any Tax Benefit Payment agreed to by the Corporate Taxpayer and any Members as due
and payable but unpaid as of the effective date of the Change of Control, and (z) without duplication, any Tax Benefit Payment
not yet due for any Taxable Year ending prior to, with or including the effective date of the Change of Control; provided that
procedures similar to the procedures of ‎Section 4.02 shall apply with respect to the determination of the amount payable
by the Corporate Taxpayer pursuant to this sentence. In the event of a Change of Control, the Early Termination Payment shall
be calculated utilizing the Valuation Assumptions and by substituting, in each case, the phrase “the effective date of the
Change of Control” for the term “Early Termination Date.”

 

(d)                
In the event that the Corporate Taxpayer breaches any of its material obligations under this Agreement, whether as a result
of failure to make any payment when due, failure to honor any other material obligation required hereunder or by operation of
law as a result of the rejection of this Agreement in a case commenced under the Bankruptcy Code or otherwise, then all obligations
hereunder shall be accelerated and such obligations shall be calculated as if an Early Termination Notice had been delivered on
the date of such breach and shall include, but not be limited to, (x) the Early Termination Payment calculated as if an Early
Termination Notice had been delivered on the date of a breach, (y) any Tax Benefit Payment agreed to by the Corporate Taxpayer
and any Members as due and payable but unpaid as of the date of a breach, and (z) without duplication, any Tax Benefit Payment
not yet due for the Taxable Year ending with or including the date of a breach; provided that procedures similar to the
procedures of ‎Section 4.02 shall apply with respect to the determination of the amount payable by the Corporate Taxpayer
pursuant to this sentence. Notwithstanding the foregoing, in the event that the Corporate Taxpayer breaches this Agreement, each
Member shall be entitled to elect to receive the amounts set forth in

 

    17

     

    

clauses
(x), (y) and (z) above or to seek specific performance of the terms hereof. The parties agree that the failure to make any payment
due pursuant to this Agreement within three months of the date such payment is due shall be deemed to be a breach of a material
obligation under this Agreement for all purposes of this Agreement, and that it will not be considered to be a breach of a material
obligation under this Agreement to make a payment due pursuant to this Agreement within three months of the date such payment
is due. Notwithstanding anything in this Agreement to the contrary, it shall not be a breach of this Agreement if the Corporate
Taxpayer fails to make any payment due pursuant to this Agreement when due to the extent the Corporate Taxpayer has insufficient
funds to make such payment despite using reasonable best efforts to obtain funds to make such payment (including by causing OpCo
or any other Subsidiaries to distribute or lend funds for such payment); provided that the interest provisions of ‎Section
5.02 shall apply to such late payment (unless the Corporate Taxpayer does not have sufficient cash to make such payment as a result
of limitations imposed by debt agreements to which the Corporate Taxpayer or any of its Subsidiaries is a party, in which case
‎Section 5.02 shall apply, but the Default Rate shall be replaced by the Agreed Rate); provided, further,
that the Corporate Taxpayer shall promptly (and in any event, within two (2) Business Days), pay all such unpaid payments, together
with accrued and unpaid interest thereon, immediately following such time that the Corporate Taxpayer has, and to the extent the
Corporate Taxpayer has, sufficient funds to make such payment, and the failure of the Corporate Taxpayer to do so shall constitute
a breach of this Agreement. For the avoidance of doubt, all cash and cash equivalents used or to be used to pay dividends by,
or repurchase equity securities of, the Corporate Taxpayer shall be deemed to be funds sufficient and available to pay such unpaid
payments, together with any accrued and unpaid interest thereon.

 

Section 4.02           
Early Termination Notice. If the Corporate Taxpayer chooses to exercise its right of early termination under ‎Section
4.01(b) above, the Corporate Taxpayer shall deliver to each Member notice of such intention to exercise such right (“Early
Termination Notice”) and a schedule (the “Early Termination Schedule”) specifying the Corporate Taxpayer’s
intention to exercise such right and showing in reasonable detail the calculation of the Early Termination Payment for such Member.
The Early Termination Schedule shall become final and binding on such Member thirty (30) calendar days from the first date on
which such Member has received such Schedule or amendment thereto unless such Member (i) within thirty (30) calendar days after
receiving the Early Termination Schedule, provides the Corporate Taxpayer with notice of a material objection to such Schedule
made in good faith (“Material Objection Notice”) or (ii) provides a written waiver of such right of a Material
Objection Notice within the period described in clause ‎(i) above, in which case such Schedule becomes binding on the
date the waiver is received by the Corporate Taxpayer (such thirty (30) calendar day date as modified, if at all, by clauses ‎(i)
or ‎(ii), the “Early Termination Effective Date”). If the Corporate Taxpayer and such Member, for
any reason, are unable to successfully resolve the issues raised in such notice within thirty (30) calendar days after receipt
by the Corporate Taxpayer of the Material Objection Notice, the Corporate Taxpayer and such Member shall employ the Reconciliation
Procedures.

 

    18

     

    

Section 4.03           
Payment upon Early Termination.

 

(a)                
Within three (3) Business Days after the Early Termination Effective Date, the Corporate Taxpayer shall pay to each Member
an amount equal to the Early Termination Payment in respect of such Member. Such payment shall be made by wire transfer of immediately
available funds to a bank account or accounts designated by such Member or as otherwise agreed by the Corporate Taxpayer and such
Member.

 

(b)                
 “Early Termination Payment” in respect of a Member shall equal the present value, discounted at the
Early Termination Rate as of the Early Termination Effective Date, of all Tax Benefit Payments in respect of such Member that
would be required to be paid by the Corporate Taxpayer beginning from the Early Termination Date and assuming that the Valuation
Assumptions are applied.

 

Article
V

SUBORDINATION AND LATE PAYMENTS

 

Section 5.01           
Subordination. Notwithstanding any other provision of this Agreement to the contrary, any Tax Benefit Payment or
Early Termination Payment required to be made by the Corporate Taxpayer to any Member under this Agreement shall rank subordinate
and junior in right of payment to any principal, interest or other amounts due and payable in respect of any obligations in respect
of indebtedness for borrowed money of the Corporate Taxpayer and its Subsidiaries (“Senior Obligations”) and
shall rank pari passu with all current or future unsecured obligations of the Corporate Taxpayer that are not Senior Obligations.

 

Section 5.02           
Late Payments by the Corporate Taxpayer. The amount of all or any portion of any Tax Benefit Payment or Early Termination
Payment not made to the applicable Member when due under the terms of this Agreement shall be payable together with any interest
thereon, computed at the Default Rate and commencing from the date on which such Tax Benefit Payment or Early Termination Payment
was due and payable, subject to ‎Section 4.01(d).

 

Article
VI

NO DISPUTES; CONSISTENCY; COOPERATION

 

Section 6.01           
Participation in the Corporate Taxpayer’s and OpCo’s Tax Matters. Except as otherwise provided herein,
the Corporate Taxpayer shall have full responsibility for, and sole discretion over, Tax matters concerning the Corporate Taxpayer
and OpCo, including the preparation, filing or amending of any Tax Return. Notwithstanding the foregoing, the Corporate Taxpayer
shall notify a Member of, and keep such Member reasonably informed with respect to, the portion of any audit, examination, or
any other administrative or judicial proceeding (a “Tax Proceeding”) of the Corporate Taxpayer and OpCo by
a Taxing Authority the outcome of which is

 

    19

     

    

reasonably
expected to affect the rights and obligations of such Member under this Agreement, and shall provide to such Member reasonable
opportunity to provide information and other input (at such Member’s own expense) to the Corporate Taxpayer, OpCo and their
respective advisors concerning the conduct of (but, for the avoidance of doubt, such Member may not control) any such portion
of such Tax Proceeding. In addition, the Corporate Taxpayer shall not, without the prior consent of the Continuing LLC Owner (such
consent not to be unreasonably withheld, conditioned or delayed), settle any Tax Proceeding in a manner that would affect in any
material respect the amounts payable to the Members under this Agreement; provided, however, that the Corporate Taxpayer
and OpCo shall not be required to take any action that is inconsistent with any provision of the LLC Agreement.

 

Section 6.02           
Consistency. The Corporate Taxpayer and the Members agree to report and cause to be reported for all purposes, including
federal, state and local Tax purposes and financial reporting purposes, all Tax-related items (including the Basis Adjustments
and each Tax Benefit Payment) in a manner consistent with that specified by the Corporate Taxpayer in any Schedule required to
be provided by or on behalf of the Corporate Taxpayer under this Agreement unless otherwise required by law. Any dispute as to
required Tax or financial reporting shall be subject to ‎Section 7.09.

 

Section 6.03           
Cooperation. Each of the Corporate Taxpayer and each Member shall (a) furnish to the other party in a timely manner
such information, documents and other materials as the other party may reasonably request for purposes of making any determination
or computation necessary or appropriate under this Agreement, preparing any Tax Return or contesting or defending any audit, examination
or controversy with any Taxing Authority, (b) make itself available to the other party and its representatives to provide explanations
of documents and materials and such other information as the other party or its representatives may reasonably request in connection
with any of the matters described in clause ‎(a) above, and (c) reasonably cooperate in connection with any such matter,
and the Corporate Taxpayer shall reimburse the applicable Member for any reasonable third-party costs and expenses incurred pursuant
to this ‎Section 6.03.

 

Article
VII

MISCELLANEOUS

 

Section 7.01           
Notices. All notices, requests and other communications to any party hereunder shall be in writing (including facsimile
transmission and electronic mail (“e- mail”) transmission, so long as a receipt of such e-mail is requested
and received) and shall be given to such party as set forth below, or pursuant to such other instructions as may be designated
in writing by the party to receive such notice:

 

If
to the Corporate Taxpayer, to: Arog

Pharmaceuticals Holdings, Inc.

[Address]

 

    20

     

    

Attention: [•]

E-mail: [•]

 

With copies (which shall
not constitute notice) to:

Davis Polk & Wardwell
LLP 450 Lexington Avenue

New York, NY 10017

Attention:Sophia
Hudson.

Michael Mollerus

E-mail:sophia.hudson@davispolk.com

michael.mollerus@davispolk.com

 

If to the applicable
Member, to the address, facsimile number or e-mail address specified for such party on the Member Schedule to the LLC Agreement.

 

All such notices,
requests and other communications shall be deemed received on the date of receipt by the recipient thereof if received prior to
Error! Bookmark not defined.:00 p.m. on a Business Day in the place of receipt. Otherwise, any such notice, request or
communication shall be deemed to have been received on the next succeeding Business Day in the place of receipt.

 

Section 7.02           
Binding Effect; Benefit; Assignment.

 

(a)                
The provisions of this Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective
successors and assigns. No provision of this Agreement is intended to confer any rights, benefits, remedies, obligations or liabilities
hereunder upon any Person other than the parties hereto and their respective successors and assigns. The Corporate Taxpayer shall
require and cause any direct or indirect successor (whether by purchase, merger, consolidation or otherwise) to all or substantially
all of the business or assets of the Corporate Taxpayer, by written agreement, expressly to assume and agree to perform this Agreement
in the same manner and to the same extent that the Corporate Taxpayer would be required to perform if no such succession had taken
place.

 

(b)                
A Member may assign any of its rights under this Agreement to any Person as long as such transferee has executed and delivered,
or, in connection with such transfer, executes and delivers, a joinder to this Agreement, in form of Exhibit A, agreeing to become
a “Member” for all purposes of this Agreement, except as otherwise provided in such joinder; provided, that
a Member’s rights under this Agreement shall be assignable by such Member under the procedure in this ‎Section
7.02(b) regardless of whether such Member continues to hold any interests in OpCo or the Corporate Taxpayer or has fully transferred
any such interests.

 

Section 7.03           
Resolution of Disputes.

 

(a)                
 Except for Reconciliation Disputes subject to ‎Section 7.09, any and all disputes which cannot be settled amicably,
including any ancillary claims of any party, arising out of, relating to or in connection with the validity, negotiation,

 

    21

     

    

execution,
interpretation, performance or non-performance of this Agreement (including the validity, scope and enforceability of this arbitration
provision) (each a “Dispute”) shall be finally settled by arbitration conducted by a single arbitrator in Delaware
in accordance with the then-existing Rules of Arbitration of the International Chamber of Commerce. If the parties to the Dispute
fail to agree on the selection of an arbitrator within ten (10) days of the receipt of the request for arbitration, the International
Chamber of Commerce shall make the appointment. The arbitrator shall be a lawyer admitted to the practice of law in the State
of Delaware and shall conduct the proceedings in the English language. Performance under this Agreement shall continue if reasonably
possible during any arbitration proceedings.

 

(b)                
Notwithstanding the provisions of paragraph ‎(a), the Corporate Taxpayer may bring an action or special proceeding
in any court of competent jurisdiction for the purpose of compelling a party to arbitrate, seeking temporary or preliminary relief
in aid of an arbitration hereunder, and/or enforcing an arbitration award and, for the purposes of this paragraph ‎(b),
each Member (i) expressly consents to the application of paragraph ‎(c) of this ‎Section 7.03 to any such
action or proceeding, (ii) agrees that proof shall not be required that monetary damages for breach of the provisions of this
Agreement would be difficult to calculate and that remedies at law would be inadequate, and (iii) irrevocably appoints the Corporate
Taxpayer as agent of such Member for service of process in connection with any such action or proceeding and agrees that service
of process upon such agent, who shall promptly advise such Member of any such service of process, shall be deemed in every respect
effective service of process upon such Member in any such action or proceeding.

 

(c)                
EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE JURISDICTION OF THE CHANCERY COURT OF THE STATE OF DELAWARE OR, IF SUCH COURT
DECLINES JURISDICTION, THE COURTS OF THE STATE OF DELAWARE SITTING IN WILMINGTON, DELAWARE, AND OF THE UNITED STATES DISTRICT
COURT FOR THE DISTRICT OF DELAWARE SITTING IN WILMINGTON, DELAWARE, AND ANY APPELLATE COURT FROM ANY THEREOF, FOR THE PURPOSE
OF ANY JUDICIAL PROCEEDING BROUGHT IN ACCORDANCE WITH THE PROVISIONS OF THIS ‎SECTION 7.03, OR ANY JUDICIAL PROCEEDING
ANCILLARY TO AN ARBITRATION OR CONTEMPLATED ARBITRATION ARISING OUT OF OR RELATING TO OR CONCERNING THIS AGREEMENT.

 

Such ancillary judicial proceedings
include any suit, action or proceeding to compel arbitration, to obtain temporary or preliminary judicial relief in aid of arbitration,
or to confirm an arbitration award. The parties acknowledge that the fora designated by this paragraph ‎(c)
have a reasonable relation to this Agreement, and to the parties’ relationship with one another.

 

(d)                
The parties hereby waive, to the fullest extent permitted by applicable law, any objection which they now or hereafter
may have to personal jurisdiction or to the laying of venue of any such ancillary suit, action or proceeding

 

    22

     

    

brought
in any court referred to in the preceding paragraph of this ‎Section 7.03 and such parties agree not to plead or claim
the same.

 

Section 7.04           
Counterparts. This Agreement may be signed in any number of counterparts, each of which shall be an original, with
the same effect as if the signatures thereto and hereto were upon the same instrument. Until and unless each party has received
a counterpart hereof signed by the other party hereto, this Agreement shall have no effect and no party shall have any right or
obligation hereunder (whether by virtue of any other oral or written agreement or other communication).

 

Section 7.05           
Entire Agreement. This Agreement [and the other Reorganization Documents]2 (as such term is defined in
the LLC Agreement) constitute the entire agreement between the parties with respect to the subject matter of this Agreement and
supersede all prior agreements and understandings, both oral and written, between the parties with respect to the subject matter
of this Agreement. Nothing in this Agreement shall create any third-party beneficiary rights in favor of any Person or other party
hereto.

 

Section 7.06           
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent
jurisdiction or other Governmental Authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants
and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated
so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse
to any party. Upon such a determination, the parties shall negotiate in good faith to modify this Agreement so as to effect the
original intent of the parties as closely as possible in an acceptable manner in order that the transactions contemplated hereby
are consummated as originally contemplated to the fullest extent possible.

 

Section 7.07           
Amendment. No provision of this Agreement may be amended unless such amendment is approved in writing by the Corporate
Taxpayer and by Persons who would be entitled to receive at least two-thirds of the Early Termination Payments payable to all
Persons entitled to Early Termination Payments under this Agreement if the Corporate Taxpayer had exercised its right of early
termination on the date of the most recent Exchange prior to such amendment (excluding, for purposes of this sentence, all payments
made to any Persons pursuant to this Agreement since the date of such most recent Exchange); provided, that no such amendment
shall be effective if such amendment will have a disproportionate effect on the payments certain Persons will or may receive under
the Tax Receivable Agreements unless all such Persons disproportionately affected consent in writing to such amendment. No provision
of this Agreement may be waived unless such waiver is in writing and signed by the party against whom the waiver is to be effective.

 

Section 7.08           
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware,
without regard to the

 

 

 

 

2
Note to Draft: To be confirmed.

 

    23

     

    

conflicts
of law rules of such State that would result in the application of the laws of any other State.

 

Section 7.09           
Reconciliation. In the event that the Corporate Taxpayer and a Member are unable to resolve a disagreement with
respect to the matters governed by Sections ‎2.03, ‎3.01(b), ‎4.02 and ‎6.02 within
the relevant period designated in this Agreement (“Reconciliation Dispute”), the Reconciliation Dispute shall
be submitted for determination to a nationally recognized expert (the “Expert”) in the particular area of disagreement
mutually acceptable to both parties. The Expert shall be a partner or principal in a nationally recognized accounting or law firm,
and unless the Corporate Taxpayer and such Member agree otherwise, the Expert shall not, and the firm that employs the Expert
shall not, have any material relationship with the Corporate Taxpayer or such Member or other actual or potential conflict of
interest. If the parties are unable to agree on an Expert within fifteen (15) calendar days of receipt by the respondent(s) of
written notice of a Reconciliation Dispute, the Expert shall be appointed by the International Chamber of Commerce Centre for
Expertise. The Expert shall resolve any matter relating to the Exchange Basis Schedule or an amendment thereto or the Early Termination
Schedule or an amendment thereto within thirty (30) calendar days and shall resolve any matter relating to a Tax Benefit Schedule
or an amendment thereto within fifteen (15) calendar days or as soon thereafter as is reasonably practicable, in each case after
the matter has been submitted to the Expert for resolution. Notwithstanding the preceding sentence, if the matter is not resolved
before any payment that is the subject of a disagreement would be due (in the absence of such disagreement) or any Tax Return
reflecting the subject of a disagreement is due, the undisputed amount shall be paid on the date prescribed by this Agreement
and such Tax Return may be filed as prepared by the Corporate Taxpayer, subject to adjustment or amendment upon resolution. The
costs and expenses relating to the engagement of such Expert or amending any Tax Return shall be borne by the Corporate Taxpayer,
except as provided in the next sentence. The Corporate Taxpayer and such Member shall bear their own costs and expenses of such
proceeding, unless (i) the Expert substantially adopts such Member’s position, in which case the Corporate Taxpayer shall
reimburse such Member for any reasonable out-of-pocket costs and expenses in such proceeding, or (ii) the Expert substantially
adopts the Corporate Taxpayer’s position, in which case such Member shall reimburse the Corporate Taxpayer for any reasonable
out-of-pocket costs and expenses in such proceeding. Any dispute as to whether a dispute is a Reconciliation Dispute within the
meaning of this ‎Section 7.09 shall be decided by the Expert. The Expert shall finally determine any Reconciliation
Dispute and the determinations of the Expert pursuant to this ‎Section 7.09 shall be binding on the Corporate Taxpayer
and such Member and may be entered and enforced in any court having jurisdiction.

 

Section 7.10           
Withholding. The Corporate Taxpayer shall be entitled to deduct and withhold from any payment payable pursuant to
this Agreement such amounts as the Corporate Taxpayer is required to deduct and withhold with respect to the making of such payment
under the Code or any provision of state, local or foreign tax law. To the extent that amounts are so withheld and paid over to
the appropriate Taxing Authority by

 

    24

     

    

the
Corporate Taxpayer, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the applicable
Member.

 

Section 7.11           
Admission of the Corporate Taxpayer into a Consolidated Group; Transfers of Corporate Assets.

 

(a)                
If the Corporate Taxpayer is or becomes a member of an affiliated or consolidated group of corporations that files a consolidated
income tax return pursuant to Sections 1501 et seq. of the Code or any corresponding provisions of state or local law, then: (i)
the provisions of this Agreement shall be applied with respect to the group as a whole; and (ii) Tax Benefit Payments, Early Termination
Payments and other applicable items hereunder shall be computed with reference to the consolidated taxable income of the group
as a whole.

 

(b)                
If any entity that is obligated to make a Tax Benefit Payment or Early Termination Payment hereunder transfers one or more
assets to a corporation (or a Person classified as a corporation for U.S. federal income tax purposes) with which such entity
does not file a consolidated tax return pursuant to Section 1501 of the Code, such entity, for purposes of calculating the amount
of any Tax Benefit Payment or Early Termination Payment (e.g., calculating the gross income of the entity and determining the
Realized Tax Benefit of such entity) due hereunder, shall be treated as having disposed of such asset in a fully taxable transaction
on the date of such contribution. The consideration deemed to be received by such entity shall be equal to the fair market value
of the contributed asset.

 

(c)                
For purposes of this ‎Section 7.11 a transfer of a partnership interest shall be treated as a transfer of the
transferring partner’s share of each of the assets and liabilities of that partnership.

 

Section 7.12           
Confidentiality. [Section 12.11 (Confidentiality)]3 of the LLC Agreement as of the date of this Agreement
shall apply to any information of the Corporate Taxpayer provided to the Members and their assignees pursuant to this Agreement.

 

Section 7.13           
Change in Law. Notwithstanding anything herein to the contrary, if, in connection with an actual or proposed change
in law, a Member reasonably believes that the existence of this Agreement could cause income (other than income arising from receipt
of a payment under this Agreement) recognized by such Member (or direct or indirect equity holders in such Member) upon an Exchange
to be treated as ordinary income rather than capital gain (or otherwise taxed at ordinary income rates) for U.S. federal income
tax purposes or would have other material adverse tax consequences to the Corporate Taxpayer or such Member or any direct or indirect
owner of a Member, then at the election of such Member and to the extent specified by such Member, this Agreement (i) shall cease
to have further effect with respect to such Member, (ii) shall not apply to an Exchange occurring after a date specified by such

 

 

 

3
Note to Draft: To be confirmed.

 

    25

     

    

Member,
or (iii) shall otherwise be amended in a manner determined by such Member; provided, that such amendment shall not result
in an increase in payments under this Agreement to such Member at any time as compared to the amounts and times of payments that
would have been due to such Member in the absence of such amendment.

 

Section 7.14           
Partnership Agreement. This Agreement shall be treated as part of the partnership agreement of OpCo as described
in Section 761(c) of the Code, and Sections 1.704-1(b)(2)(ii)(h) and 1.761-1(c) of the Treasury Regulations.

 

[Remainder
of Page Intentionally Left Blank]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    26

     

    

IN WITNESS
WHEREOF, the Corporate Taxpayer, OpCo, and each Member set forth below have duly executed this Agreement as of the date first
written above.

 

 

 

	 	 	CORPORATE TAXPAYER
	 	 	 
	 	 	 
	 	 AROG PHARMACEUTICALS HOLDINGS, INC.
	 	 	 
	 	 	 
	 	By:      	[•]
	 	 	 
	 	Name: 	[•]
	 	 	 
	 	Title:   	[•]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Signature
Page to Tax Receivable Agreement]

 

    27

     

    

 

 

 

	 	 	 
OPCO
	 	 	 
	 	 	 
	 	 
AROG PHARMACEUTICALS LLC
	 	 	 
	 	 	 
	 	By:      	[•]
	 	 	 
	 	Name: 	[•]
	 	 	 
	 	Title:   	[•]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Signature
Page to Tax Receivable Agreement]

 

    28

     

    

 MEMBER(S)

 

 By:
[•]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Signature
Page to Tax Receivable Agreement]

 

    29

     

    

Exhibit
A

Form of Joinder

 

This JOINDER
(this “Joinder”) to the Tax Receivable Agreement (as defined below), dated as of , by and among Arog Pharmaceuticals
Holdings, Inc., a Delaware corporation (the “Corporate Taxpayer”), and(“Permitted Transferee”).

 

WHEREAS, on
__________________, Permitted Transferee acquired (the “Acquisition”) the right to receive any and all payments that
may become due and payable under the Tax Receivable Agreement with respect to _______Common Units and the corresponding shares
of Class B Common Stock that were previously, or may in the future be, Exchanged and are described in greater detail in Annex
A to this Joinder (collectively, “Interests” and, together with all other interests hereinafter acquired by the Permitted
Transferee from Transferor, the “Acquired Interests”) from _________ (“Transferor”); and

 

WHEREAS, Transferor,
in connection with the Acquisition, has required Permitted Transferee to execute and deliver this Joinder pursuant to ‎Section
7.02(b) of the Tax Receivable Agreement, dated as of [ ], 2018, by and among the Corporate Taxpayer and each Member (as defined
therein) (the “Tax Receivable Agreement”).

 

NOW, THEREFORE,
in consideration of the foregoing and the respective covenants and agreements set forth herein, and intending to be legally bound
hereby, the parties hereto agree as follows:

 

Section 1.01      Definitions.
To the extent capitalized words used in this Joinder are not defined in this Joinder, such words shall have the respective meanings
set forth in the Tax Receivable Agreement.

 

Section 1.02      Joinder.
Permitted Transferee hereby acknowledges and agrees to become a “Member” (as defined in the Tax Receivable Agreement)
for all purposes of the Tax Receivable Agreement. Permitted Transferee hereby acknowledges the terms of ‎Section
7.02(b) of the Tax Receivable Agreement and agrees to be bound by ‎Section
7.12 of the Tax Receivable Agreement.

 

Section 1.03      Notice.
Any notice, request, consent, claim, demand, approval, waiver or other communication hereunder to Permitted Transferee shall be
delivered or sent to Permitted Transferee at the address set forth on the signature page hereto in accordance with ‎Section
7.01 of the Tax Receivable Agreement.

 

Section 1.04      Governing
Law. This Joinder shall be governed by and construed in accordance with the laws of the State of Delaware, without regard
to the conflicts of law rules of such State that would result in the application of the laws of any other State.

 

IN WITNESS
WHEREOF, this Joinder has been duly executed and delivered by Permitted Transferee as of the date first above written.

 

    30

     

    

	 	[PERMITTED TRANSFEREE]
	 	 
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 	 
	 	 	 
	 	Address for notices:

 

 

 

 

 

 

 

 

 

    31Exhibit 10.10

 

ASSET PURCHASE AGREEMENT

 

This Asset Purchase
Agreement (this  “Agreement”) is made and entered into effective as of January 5, 2015 (the  “Effective
Date”), by and between Arog Pharmaceuticals, Inc., a Delaware corporation ( “Seller”), and Videra Pharmaceuticals,
LLC a Delaware limited liability company ( “Buyer”). Seller and Buyer are sometimes referred to herein as the
 “Parties,” and each, a  “Party.”

 

RECITALS

 

WHEREAS, Seller desires
to contribute, transfer, assign, convey, set over, grant sell and deliver (collectively,  “Transfer”) to Buyer
the assets identified on Exhibit A attached hereto (the  “Purchased Assets”) free and clear of all Liens
other than Permitted Liens; and

 

WHEREAS, the aggregate
consideration for the Purchased Assets shall be One Hundred Twenty Five Thousand Dollars ($125,000) (the  “Purchase Price”)
and Buyer’s assumption of certain liabilities of Seller identified on Exhibit B attached hereto (the  “Assumed
Liabilities”).

 

NOW, THEREFORE, in
consideration of the mutual agreements set forth herein, and subject to the terms and provisions set forth below, the Parties hereto
agree as follows:

 

AGREEMENT

 

1. Defined Terms.
For purposes of this Agreement, the terms defined in this Section 1 shall have the meanings herein specified unless the context
otherwise requires.

 

1.1  “Contract”
means any written or oral legally binding contract, agreement, instrument, commitment or undertaking of any nature.

 

1.2
 “Excluded Assets” means any assets of Seller that are not Purchased Assets.

 

1.3  “Governmental Entity” means any: (a) nation, state, county, city, district or other similar jurisdiction of
any nature; (b) federal, state, local or foreign government; (c) governmental or quasi-governmental authority of any nature (including
any governmental agency, branch, commission, bureau, instrumentality, department, official, entity, court or tribunal); (d) multinational
organization or body; or (e) body or other Person entitled by applicable Law, contract or other arrangement to exercise any arbitrative,
administrative, certification, executive, judicial, legislative, licensing, police, regulatory or taxing authority or power.

 

1.4  
 “Law” means any applicable provision of any constitution, treaty, statute, law (including the common law), rule,
regulation, ordinance, code or order enacted, adopted, issued or promulgated by any Governmental Entity.

 

1.5  
 “Liability” means any liability or obligation of any kind or nature (whether known or unknown, asserted or unasserted,
absolute or contingent, accrued or unaccrued, liquidated or unliquidated, or due or to become due).

 

     

     

    

1.6  
 “Lien” means any mortgage, claim, pledge, security interest, charge, lien, option or other right to purchase,
restriction or reservation or any other encumbrance whatsoever.

 

1.7 
 “Material Adverse Effect” means, with respect to any Person, any incident, condition, change, effect or circumstance
that, individually or when taken together with all such incidents, conditions, changes, effects or circumstances in the aggregate,
has had or would reasonably be expected to have a material adverse effect on the business, operations, condition (financial or
otherwise), properties, Liabilities, results of operations or prospects of such Person and its subsidiaries, taken as a whole or
any of them taken individually.

 

1.8 
 “Permitted Lien” means any: (a) Lien for any tax, assessment or other governmental charge that is not yet due
and payable or that may thereafter be paid without penalty; or (b) mechanic’s, materialmen’s, landlord’s or similar
Lien arising or incurred in the ordinary course of business of the applicable Person that secures any amount that is not overdue;
or (c) any license to intellectual property rights.

 

1.9 
 “Person” means any individual, partnership, corporation, limited liability company, association, joint stock
company, trust, joint venture, unincorporated organization or any other business entity or association or any Governmental Entity.

 

2.   Transfer
of Assets; Assumption of Liabilities: Issuance of Shares. The closing (the  “Closing”) of the transactions
contemplated by this Agreement (the  “Asset Sale”) shall be consummated effective as of 12:01 a.m. Central
Time on the Effective Date. At the Closing, (i) Seller shall Transfer the Purchased Assets to Buyer, free and clear of all Liens
other than Permitted Liens, and (ii) Buyer shall assume the Assumed Liabilities and pay to Seller the Purchase Price via wire
transfer of immediately available funds to an account designated by Seller. In connection with the Asset Sale, at the Closing,
Seller and Buyer shall enter into (A) an Assignment and Assumption Agreement and Bill of Sale substantially in the form attached
hereto as Exhibit C, (B) a Patent Assignment substantially in the form attached hereto as Exhibit D  and (B) a License Agreement
substantially in the form attached hereto as Exhibit E. The Parties acknowledge that no consideration, other than as specifically
recited herein, is or will be received by Seller in exchange for the Transfer of the Purchased Assets set forth herein. Notwithstanding
any other provision of this Agreement, Buyer shall not assume any Liabilities of Seller nor any affiliate of Seller other than
the Assumed Liabilities.

 

3.
Representations and Warranties.

 

3.1 
Representations and Warranties of Seller. Seller represents and warrants to Buyer as of the Effective Date as follows:

 

(a)  
Organization and Standing. Seller is a corporation duly organized and validly existing under the Laws of the State of Delaware.
Seller has the requisite corporate power and authority to own the Purchased Assets and to conduct its business as now being conducted,
and is duly qualified to do business and is in good standing in each jurisdiction in which the ownership or leasing of its properties
or assets or the conduct of its business requires such qualification, except where the failure to be so qualified or in good standing
has not had and would not reasonably be expected to have a Material Adverse Effect on Seller.

 

 

    2 

     

    

(b)  
Authority . Seller has the requisite company power and authority to execute and deliver and perform its obligations under
this Agreement and to consummate the transactions contemplated hereby. The execution and delivery of” this Agreement and
the consummation of the transactions contemplated hereby have been duly authorized by all necessary corporate action on the part
of Seller. This Agreement has been duly executed and delivered by Seller and constitutes the legal, valid and binding obligations
of Seller, enforceable against Seller in accordance with its terms, except to the extent that enforceability may be limited by
the effect, if any, of any applicable bankruptcy, reorganization, insolvency, moratorium or other Laws affecting the enforcement
of creditors’ rights generally or any general principles of equity, regardless of whether such enforceability is considered
in a proceeding at law or in equity. Neither the execution and delivery by Seller of this Agreement nor the consummation of the
transactions contemplated hereby will conflict with or violate any provision of Seller’ s Certificate of Incorporation or
Bylaws, each as amended to date.

 

(c)  
Governmental Approvals. No consent, approval, order or authorization of, or registration, qualification, designation, declaration
or filing with any Governmental Entity, is required on the part of Seller in connection with the Transfer of the Purchased Assets
to Seller and the other transactions contemplated by this Agreement and the other documents contemplated hereby.

 

3.2 
Representations and Warranties of Buyer. Buyer represents and warrants to Seller as of the Effective Date as follows:

 

(a)  
Organization and Standing. Buyer is a limited liability company duly organized and validly existing under the Laws of the
State of Delaware. Buyer has the requisite company power and authority to own its assets and properties and to carry on its business
as now being conducted and is duly qualified to do business and is in good standing in each jurisdiction in which the ownership
or leasing of its properties or assets or the conduct of its business requires such qualification, except where the failure to
be so qualified or in good standing has not had and would not reasonably be expected to have a Material Adverse Effect on Buyer.

 

(b)  
Authority. Buyer has the requisite company power and authority to execute and deliver and perform its obligations under
this Agreement and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement and the consummation
of the transactions contemplated hereby have been duly authorized by all necessary corporate action on the part of Buyer. This
Agreement has been duly executed and delivered by Buyer and constitutes the legal, valid and binding obligations of Buyer, enforceable
against Buyer in accordance with its terms, except to the extent that enforceability may be limited by the effect, if any, of any
applicable bankruptcy, reorganization, insolvency, moratorium or other Laws affecting the enforcement of creditors’ rights
generally or any general principles of equity, regardless of whether such enforceability is considered in a proceeding at law or
in equity. Neither the execution and delivery by Buyer of this Agreement nor the consummation of the transactions contemplated
hereby will conflict with or violate any provision of Buyer’s Certificate of Formation or Limited Liability Company Agreement,
each as amended to date.

 

 

    3 

     

    

(c)  Governmental Approvals.
No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any Governmental
Entity is required on the part of Buyer in connection with the receipt of the Purchased Assets, assumption of the Assumed Liabilities
and the other transactions contemplated by this Agreement and the other documents contemplated hereby.

 

3.3 The representations
and warranties of Seller and the Buyer contained in Section 3 of this Agreement shall expire and be of no further force
or effect as of the date that is twelve (12) months after the date of the Closing.

 

4. Notices. All
notices and other communications hereunder shall be in writing and shall be deemed received (a) on the date of delivery if delivered
personally or by messenger service, (b) on the date of confirmation of receipt of transmission by facsimile (or, the first business
day following such receipt if (i) the date is not a business day or (ii) confirmation of receipt is given after 5:00 p.m., Pacific
Time) or (c) on the date of confirmation of receipt if delivered by a nationally recognized courier service (or, the first business
day following such receipt if (i) the date is not a business day or (ii) confirmation of receipt is given after 5:00 p.m., Pacific
Time), to the Parties at the following address or facsimile numbers (or at such other address or facsimile number for a Party as
shall be specified by like notice):

 

if to Seller, to:

 

Arog Pharmaceuticals, Inc.

Two Lincoln Centre 

5420 LBJ Freeway, Suite 410

Dallas, Texas 75240 

Fax: (469) 533-3966

Attention: CEO

 

if to Buyer, to:

 

Videra Pharmaceuticals, LLC 

Two Lincoln Centre

5420 LBJ Freeway, Suite 410 

Dallas, Texas 75240

Fax: (214) 889-7070 

Attention: CEO

 

5.  
Amendment. The Parties may cause this Agreement to be amended at any time by execution of an instrument in writing signed
on behalf of each of the Parties, except as otherwise required by Law.

 

6.  
Further Assurances. Each Party hereto shall, from time to time after the Closing, at the request of any other Party hereto
in writing and without further consideration, execute and deliver such other instruments of conveyance, assignment, transfer and
assumption, and take such other actions, as such other Party may reasonably request to more effectively consummate the transactions
contemplated by this Agreement.

 

 

    4 

     

    

7.  
Wrong Pocket. In the event that after the Closing, Seller or any of its affiliates receives any payment related to any Purchased
Asset, Seller agrees to use commercially reasonable efforts to remit any such payment within five (5) business days (or cause to
be remitted within five (5) business days) such funds to Buyer, but in any event such funds shall be remitted to Buyer as soon
as possible thereafter. In the event that Buyer or any of its affiliates receives any payment related to any Excluded Assets after
the Closing, Buyer agrees to use commercially reasonable efforts to remit any such payment within five (5) business days (or cause
to be remitted within five (5) business days) such funds to Seller, but in any event such funds shall be remitted to Seller as
soon as possible thereafter.

 

8.   Assignment:
Successors and Assigns. None of the rights and obligations of Seller or Buyer may be assigned without the prior written consent
of Buyer or Seller, respectively, and any purported assignment made without such consent shall be void; provided, however,
that the rights and obligations of a Party may be assigned and delegated without the other Party’s consent (a)  in
connection with a transfer, merger, acquisition, reorganization or consolidation of such Party, or with a sale of all or substantially
all of such Party’ s assets, (b) to any affiliate of such Party, or (c) to any successor Person who purchases the business
of such Party. Subject to the foregoing, this Agreement (and the rights and obligations hereunder) shall be binding upon and shall
inure to the benefit of the Parties hereto and their respective successors and permitted assigns (each of which successors and
permitted assigns shall be deemed to be a Party hereto for all purposes of this Agreement).

 

9.  
Waiver. Any Party may, to the extent legally allowed, (a) extend the time for the performance of any of the obligations
or other acts of the other Party, (b) waive any inaccuracies in the representations and warranties made to such Party contained
herein or in any document delivered pursuant hereto and (c) waive compliance with any of the agreements or conditions for the benefit
of such Party contained herein. Any such extension or waiver by any Party shall not operate or be construed as a further or continuing
extension or waiver. Any agreement on the part of a Party to any such extension or waiver shall be valid only if set forth in an
instrument in writing signed on behalf of such Party.

 

10.    
Severability. In the event that any provision of this Agreement, or the application thereof, becomes or is declared by a
court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement will continue in full force
and effect and the application of such provision to other Persons or circumstances will be interpreted so as reasonably to effect
the intent of the Parties.

 

11.    
Governing Law. This Agreement and all disputes and controversies arising hereunder shall be governed by and construed in
accordance with the Laws of the State of Delaware without reference to such state’s principles of conflicts of law.

 

12.    
Waiver of Jury Trial. EACH PARTY WAIVES ANY RIGHT TO TRIAL BY JURY IN ANY DISPUTE, WHETHER SOUNDING IN CONTRACT, TORT, OR
OTHERWISE, AMONG THE PARTIES ARISING OUT OF OR RELATED TO THE TRANSACTIONS CONTEMPLATED HEREBY. ANY PARTY MAY FILE AN ORIGINAL
COUNTERPART OR A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF

 

 

    5 

     

    

THE CONSENT OF THE PARTIES TO THE WAIVER OF THEIR RIGHT TO TRIAL
BY JURY.

 

13.    
Attorneys’ Fees. Should any party institute any proceeding in court or otherwise to enforce any provision hereof or
for damages by reason of alleged breach of any provision of this Agreement, the prevailing party shall be entitled to receive from
the non-prevailing party such reasonable out-of-pocket expenses (including attorneys’ fees and expenses) incurred by the
prevailing party in connection with any such proceeding.

 

14.    
Counterpart Execution. This Agreement may be executed in one or more counterparts, all of which shall be considered one
and the same agreement and shall become effective when one or more counterparts have been signed by each of the Parties and delivered
to the other Party, it being understood that all Parties need not sign the same counterpart. The Parties may sign this Agreement
in the original, by facsimile, by .PDF or by any other generally acceptable electronic means.

 

15.    
Interpretation; Construction. In this Agreement: (a) the section headings are for convenience of reference only and will
not affect the meaning or interpretation of this Agreement; (b) the words  “herein,”  “hereunder,”
 “hereby” and similar words refer to this Agreement as a whole (and not to the particular sentence, paragraph
or section where they appear); (c) terms used in the plural include the singular, and vice versa, unless the context clearly requires
otherwise; (d) unless expressly stated herein to the contrary, reference to any document means such document as amended or modified
and as in effect from time to time in accordance with the terms thereof; (e) unless expressly stated herein to the contrary, reference
to any applicable Law means such applicable Law as amended, modified, codified, replaced or reenacted, in whole or in part, and
as in effect from time to time, including any rule or regulation promulgated thereunder; (f) the words  “including,”
 “include” and variations thereof are deemed to be followed by the words  “ without limitation;”
(g)  “or” is used in the sense of  “and/or;”  “any” is used in the sense of
 “any or all;” and  “with respect to” any item includes the concept  “of’ such
item or  “under” such item or any similar relationship regarding such item; (h) unless expressly stated herein
to the contrary, reference to a document, including this Agreement, will be deemed to also refer to each annex, addendum, exhibit,
schedule or other attachment thereto; (i) unless expressly stated herein to the contrary, reference to a section, schedule or
exhibit is to a section, schedule or exhibit, respectively, of this Agreement; (j) when calculating a period of time, the day
that is the initial reference day in calculating such period will be excluded and, if the last day of such period is not a business
day, such period will end on the next day that is a business day; (k)  with respect to all dates and time periods in or referred
to in this Agreement, time is of the essence; and (l) the phrase  “the date hereof ‘ means the date of this Agreement,
as stated in the first paragraph hereof.

 

[Remainder of page intentionally Left blank]

 

 

    6 

     

    

IN WITNESS WHEREOF, the parties hereto have
caused this Agreement to be executed as of the date first set forth above.

 

 

	 	AROG PHARMACEUTICALS, INC.

                     

                     

	 	By:	/s/ Vinay Jain
	 	 	Name:	Vinay Jain, M.D.
	 	 	Title:	CEO

 

 

	 	VIDERA PHARMACEUTICALS, LLC

                     

                     

	 	By:	/s/ Vinay Jain
	 	 	Name:	Vinay Jain, M.D.
	 	 	Title:	Manager

 

     

     

    

EXHIBIT A

 

Purchased Assets

 

		1.	All of Seller’ s rights under the Contracts set forth on Schedule 1 hereto (collectively,
the  “Transferred Contracts”), including all claims, contract rights and warranty and product liability claims
against third parties under the Transferred Contracts.

 

		2.	All Intellectual Property set forth on Schedule 2 and all rights of copyright in the tangible
embodiments of the items identified below in Paragraphs 3 and 4 that are primarily related to the Purchased Assets
(collectively, the  “Transferred IP”), and all rights to sue for or assert claims against and remedies against
past, present or future infringement s or misappropriation of any or all of the Transferred IP, and rights of priority and protection
of interests therein and to retain any and all amounts therefrom.

 

		3.	All data, records, files, manuals, blueprints and other documentation primarily related to the
Purchased Assets, including: (i) service and warranty records; (ii) studies, reports, correspondence and other similar documents
and records primarily related to the Purchased Assets, whether in electronic form or otherwise; and (iv) copies of all accounting
and tax books, ledgers and records and other financial records primarily related to the Purchased Assets.

 

		4.	All policies and procedures, methods of delivery of services, disks, drawings and specifications,
market studies, consultants’ reports and prototypes, primarily related to the Purchased Assets.

 

     

     

    

EXHIBIT B

 

Assumed Liabilities

 

		1.	All Liabilities arising with respect to Buyer’ s use or exploitation of the Purchased Assets
following the Closing, including all Liabilities arising under the Transferred Contracts following the Closing.

 

     

     

    

EXHIBIT C

 

Assignment and Assumption Agreement and Bill of Sale

 

     

     

    

ASSIGNMENT AND ASSUMPTION AGREEMENT AND BILL OF
SALE

 

This Assignment and
Assumption Agreement and Bill of Sale (this  “Agreement”) is made and entered into as of January 5, 2015, by
and between Arog Pharmaceuticals, Inc., a Delaware corporation ( “Assignor”), and Videra Pharmaceuticals, LLC,
a Delaware limited liability company ( “Assignee”).

 

RECITALS

 

A. Assignor and Assignee
are parties to that certain Asset Purchase Agreement dated as the date of this Agreement (the  “Purchase Agreement”),
pursuant to which Assignor has agreed to contribute, transfer, assign, convey, set over, grant, sell and deliver ( “Transfer”)
to Assignee the Purchased Assets and Assignee has agreed to assume the Assumed Liabilities.

 

AGREEMENT

 

NOW, THEREFORE, for
and in consideration of the promises and the mutual covenants contained herein, and for other good and valuable consideration,
the receipt, adequacy and legal sufficiency of which are hereby acknowledged, the parties do hereby agree as follows:

 

1.  
Capitalized Terms. Capitalized terms used but not defined herein shall have the meanings for such terms that are set forth
in the Purchase Agreement.

 

2.  
Contribution and Transfer of Assets. Pursuant to the terms of the Purchase Agreement, Assignor hereby Transfers to Assignee
and its successors and assigns, effective as of 12:01 a.m. Central Time on the date hereof (the  “Effective Time”),
all of Assignor’s right, title and interest in and to all of the Purchased Assets free and clear of all Liens other than
Permitted Liens and the Assumed Liabilities. Effective as of the Effective Time, Assignee hereby accepts the Transfer of all of
Assignor’s right, title and interest in and to all of the Purchased Assets.

 

3.  
Assumption. Pursuant to the terms of the Purchase Agreement, effective as of the Effective Time, Assignee hereby assumes and
agrees to pay, discharge and perform all of the duties, obligations, terms, provisions and covenants of the Assumed Liabilities.
In no event does Assignee assume or otherwise have any liability for any other liability (or portion thereof) of Assignor and the
parties hereto agree that all other liabilities shall remain the sole responsibility of Assignor.

 

4.  
Third Parties. The assumption by Assignee of the Assumed Liabilities as herein provided is not intended by the parties to expand
the rights or remedies of any third party against Assignee as compared to the rights and remedies which such third party would
have had against Assignor had Assignee not consummated the transactions contemplated by the Purchase Agreement and this Agreement.
Nothing herein contained shall, or shall be construed to, prejudice the right of Assignee to contest any claim or demand by such
a third party with respect to any obligation or liability assumed hereunder, and Assignee shall be entitled to defend or contest
any such claim or demand in any and all respects from and after the date hereof.

 

     

     

    

5. Terms
of the Purchase Agreement. Nothing herein contained shall itself change, amend, extend, enlarge, limit or alter (nor shall
it be deemed or construed as changing, amending, extending, enlarging, limiting or altering) the terms or conditions of the Purchase
Agreement in any manner whatsoever. This instrument does not create or establish liabilities or obligations not otherwise created
or existing under or pursuant to the Purchase Agreement. In the event of any conflict or inconsistency between the terms of the
Purchase Agreement and the terms hereof, the terms of the Purchase Agreement shall govern.

 

6.  
Governing Law. This Agreement and all disputes and controversies arising hereunder shall be governed by and construed in accordance
with the Laws of the State of Delaware without reference to such state’s principles of conflicts of law.

 

7.  
Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their
respective successors and permitted assigns (each of which successors and permitted assigns shall be deemed to be a party hereto
for all purposes of this Agreement).

 

8.  
Severability. In the event that any provision of this Agreement, or the application thereof, becomes or is declared by a court
of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement will continue in full force and
effect and the application of such provision to other Persons or circumstances will be interpreted so as reasonably to effect the
intent of the Parties.

 

9.  
Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same
agreement and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the
other party, it being understood that all parties need not sign the same counterpart. The parties may sign this Agreement
in the original, by facsimile, by .PDF or by any other generally acceptable electronic means.

 

10.   
Transferred Contracts and Permits. Notwithstanding any other provision of this Agreement or the Purchase Agreement, this Agreement
does not constitute an agreement to assign or transfer, or effect an assignment or transfer, of any Transferred Contract or permit
if the parties have not obtained a required consent to assignment or transfer as of the Closing and an attempted assignment or
transfer thereof without the consent of a third party would constitute a breach or other contravention thereof or a violation
of law or would in any way adversely affect the rights of Assignor or Assignee or any of their affiliates thereto or thereunder.
As to any Transferred Contract or permit referred to in the previous sentence, the parties agree to continue to use commercially
reasonable efforts from and after the Closing to obtain any required consent(s).

 

[Remainder of Page Intentionally Left Blank]

 

     

     

    

IN WITNESS WHEREOF,
each of the parties has caused this Agreement to be executed on its behalf by their respective officers thereunto duly authorized
all as of the date first written above.

 

 

	 	

“ASSIGNOR”

 

AROG
PHARMACEUTICALS, INC.

 

                     

	 	By:	/s/ Vinay Jain
	 	 	Name:	Vinay Jain, M.D.
	 	 	Title:	CEO

 

 

	 	

                    “ASSIGNEE”

 

Videra
Pharmaceuticals, LLC

                     

                     

	 	By:	/s/ Vinay Jain
	 	 	Name:	Vinay Jain, M.D.
	 	 	Title:	Manager

 

 

     

     

    

EXHIBIT D

 

Patent Assignment Agreement

 

     

     

    

PATENT ASSIGNMENT

 

This PATENT ASSIGNMENT
(this  “Assignment”) is made and entered into as of January 5, 2015 (the  “Effective Date”)
by and between Arog Pharmaceuticals, Inc., a Delaware corporation ( “Assignor”), and Videra Pharmaceuticals,
LLC, a Delaware limited liability company ( “Assignee”).

 

WHEREAS, pursuant to
that certain Asset Purchase Agreement (the  “Purchase Agreement”), dated January 5, 2015 between Assignor and
Assignee, Assignor has agreed to sell, assign, transfer, convey, and deliver to Assignee all of Assignor’s right, title,
and interest in and to certain assets, including, without limitation, the Assigned Patents (defined below); and

 

WHEREAS, pursuant to
the Purchase Agreement, Assignor and Assignee have agreed to enter into this Assignment.

 

NOW, THEREFORE, in
consideration of the promises and covenants set forth in the Purchase Agreement and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

 

1.  
Conveyance. Assignor hereby sells, assigns, transfers, conveys, and delivers to Assignee and Assignee hereby accepts
all of Assignor’s right, title and interest in, to and under the issued patents and patent applications listed on Schedule
A, including, without limitation (i) all reissues, divisionals, continuations, continuations-in-part, revisions, reexaminations,
extensions, and counterparts (whether foreign or domestic) claiming priority to or based on any of the foregoing items, together
with all patents issuing therefrom, (ii) all inventions and improvements claimed or described in any of the foregoing, including
without limitation all rights of priority under international conventions, treaties, or agreements, (iii) all rights to collect
royalties and proceeds in connection with any of the foregoing (collectively (i)-(iii) above, the  “Assigned Patents”),
(iv) all rights to prosecute and maintain any of the foregoing, and (v) rights to sue and bring other claims for past, present
and future infringement, misappropriation, or other violation of any of the foregoing and all rights to recover and retain damages
(including attorneys’ fees and expenses) or lost profits in connection therewith.

 

2.  
Recordation. Assignor hereby requests the United States Patent and Trademark Office Commissioner for Patents and
any other applicable governmental entity or registrar (including any applicable foreign or international office or registrar),
to record Assignee as the assignee and owner of the Assigned Patents. Assignor also hereby authorizes the respective patent office
or governmental agency in each jurisdiction to issue any and all patents or certificates of invention which may be granted upon
any of the Assigned Patents in the name of Assignee, as the assignee to the entire interest therein.

 

3.  
Information and Assistance.

 

3.1  
Upon Assignee’s reasonable request and without further compensation, Assignor shall execute, acknowledge, and deliver
all the instruments and documents and shall take all the actions reasonably necessary or required by law to consummate and make
fully effective the transaction contemplated by this Assignment.

 

3.2  
If Assignee is unable for any reason to secure Assignor’s signature to any document required to file, prosecute, register,
or memorialize the assignment of any rights under any Assigned Patents as provided under this Assignment, Assignor hereby irrevocably
designates and appoints Assignee and Assignee’s duly authorized officers and agents as Assignor’s agents and attorneys-in-fact
to act for and on Assignor’s behalf and instead of Assignor to take all lawfully permitted acts to further the

 

     

     

    

filing, prosecution, registration, memorialization
of assignment, issuance, and enforcement of rights under such Assigned Patents, all with the same legal force and effect as if
executed by Assignor. The foregoing is deemed a power coupled with an interest and is irrevocable.

 

4.  
Successors and Assigns. This Assignment and all the provisions hereof shall be binding upon and shall inure to the
benefit of the parties hereto and their respective successors and permitted assigns. Nothing herein, express or implied, shall
give or be construed to give to any person, other than the parties hereto and such permitted assigns, any legal or equitable rights
hereunder.

 

5.  
Counterparts. This Assignment may be executed in two or more consecutive counterparts (including by facsimile), each
of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. The
Assignment shall become effective when each party has signed one or more counterparts, and delivered them (by facsimile or otherwise)
to the other party.

 

6.  
Purchase Agreement Controls. This Assignment is provided pursuant to the Purchase Agreement, to which reference is
made for a further statement of the rights and obligations of Assignor and Assignee with respect to the Assigned Patents. Nothing
contained in this Assignment shall be deemed to modify, supersede, enlarge, or affect the rights of any person under the Purchase
Agreement. If any provision of this Assignment is inconsistent or conflicts with the Purchase Agreement, the Purchase Agreement
shall control.

 

7.  
Governing Law. This Assignment and all claims or causes of action (whether in contract, tort or otherwise) that may
be based upon, arise out of or relate to this Assignment or the negotiation, execution, or performance of this Assignment shall
be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any choice or conflict
of law provision or rule.

 

[Signature Page Follows]

 

     

     

    

IN WITNESS WHEREOF, the undersigned have
caused this Patent Assignment to be executed, effective as of the Effective Date

 

	 	
        ASSIGNOR:

         

        AROG PHARMACEUTICALS, INC.

         

	 	By:	 
	 	Name:	Vinay Jain, M.D.
	 	Title:	Chief Executive Officer
	 	 	 
	 	Address :
	 	 
	 	
        Two Lincoln Centre

        

        5420 LBJ Freeway, Suite 410 

        Dallas, Texas 75240

         

	 	 
	 	Acknowledged and Accepted:
	 	 
	 	
        ASSIGNEE:

         

        VIDERA PHARMACEUTICALS, LLC

         

	 	By:	 
	 	Name:	Vinay Jain, M.D.
	 	Title:	Manager
	 	 
	 	Address:
	 	 
	 	
        Two Lincoln Centre

        

        5420 LBJ Freeway, Suite 410 

        Dallas, Texas 75240

         

 

     

     

    

SCHEDULE A TO PATENT ASSIGNMENT

 

Method of Inhibiting FLT3 Kinase

 

		·	Application Number: 14/447,139

 

		·	Filing Date: July 30, 2014

 

		o	Patent Cooperation Treaty, filed with the United States Patent and Trademark Office (USPTO)

 

		·	First Named Inventor: Vinay K. Jain

 

		·	Internal Reference Number: AROG: 1003

 

     

     

    

EXHIBIT E

 

License Agreement

 

[Filed as Exhibit 10.9 to this Registration
Statement]

 

 

     

     

    

SCHEDULE 1

 

Transferred Contracts

 

		·	New York University School of Medicine - Material Transfer Agreement

 

		o	Effective April 1, 2014

 

		o	Tuberculosis

 

		o	PI: Joel D. Ernst

 

		o	Crenolanib Besylate

 

		·	Genon Biotechnologies, Ltd.

 

		o	Effective July 12, 2013

 

		o	JAK assays for selectivity

 

		o	PI: Olli Silvennoinen

 

		o	CP-637,451

 

     

     

    

SCHEDULE 2

 

Transferred IP

 

Patent Applications

 

		·	AROG:1003

 

		o	Application No. 14/447,139

 

		o	Method of Inhibiting FLT3 Kinase - CP-673451

 

Domain Name(s)

 

		·	Viderapharma.com

 

Know-how primarily related to the Purchased Assets

 

 

     

     

    

SCHEDULE 3

 

Tangible Assets

 

Compounds

 

	Compound Number (non-GMP Materials)	Salt Name	Total Milligrams (Approximate)	Lot#
	CP-673451	Base	1,052,800	041511-124-03
	CP-673451-01	Hydrochloride salt	5,300	047886-274-01
	CP-673451-10	Citrate salt	151	Various Lot Number(s)
	CP-673451-14	Acetate salt	16	Various Lot Number(s)
	CP-673451-15	P-Touluene sulphonate salt	3,700	Various Lot Number(s)
	CP-673451-24	Succinate salt	22	Various Lot Number(s)
	CP-673451-27	 	5	Various Lot Number(s)
	CP-673451-42	 	6	Various Lot Number(s)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]